Eli Lilly and Co  

(Public, NYSE:LLY)   Watch this stock  
Find more results for Derica W. Rice
-2.40 (-2.77%)
After Hours: 84.17 0.00 (0.00%)
Oct 6, 5:13PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 82.08 - 86.50
52 week 60.58 - 92.85
Open 86.39
Vol / Avg. 5.52M/5.60M
Mkt cap 95.99B
P/E 43.69
Div/yield 0.50/2.38
EPS 1.93
Shares 1.11B
Beta 0.20
Inst. own 77%
Dec 8, 2015
Eli Lilly and Co Animal Health and Alzheimer's Disease Review - 9:00AM EST - Add to calendar
Oct 22, 2015
Q3 2015 Eli Lilly and Co Earnings Release - 9:30AM EDT - Add to calendar
Oct 22, 2015
Q3 2015 Eli Lilly and Co Earnings Call - 9:00AM EDT - Add to calendar
Sep 24, 2015
Eli Lilly and Co to Discuss EMPA-REG OUTCOME� Data Conference Call
Sep 17, 2015
Eli Lilly and Co at Morgan Stanley Healthcare Conference
Jul 23, 2015
Q2 2015 Eli Lilly and Co Earnings Release
Jul 23, 2015
Q2 2015 Eli Lilly and Co Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 12.07% 12.19%
Operating margin 12.78% 13.56%
EBITD margin - 24.00%
Return on average assets 6.72% 6.60%
Return on average equity 16.29% 14.49%
Employees 39,135 -
CDP Score - 85 B


Lilly Corporate Ctr
United States - Map
+1-317-2762000 (Phone)
+1-317-2763492 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company's products are sold in approximately 120 countries. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.

Officers and directors

John C. Lechleiter Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Derica W. Rice Chief Financial Officer, Executive Vice President - Global Services
Age: 50
Bio & Compensation  - Reuters
Maria A. Crowe President - Manufacturing Operations
Age: 55
Bio & Compensation  - Reuters
Jan M. Lundberg Ph.D. Executive Vice President - Science and Technology, President - Lilly Research Laboratories
Age: 61
Bio & Compensation  - Reuters
Melissa S. Barnes Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
Age: 46
Bio & Compensation  - Reuters
Michael J. Harrington Senior Vice President, General Counsel
Age: 52
Bio & Compensation  - Reuters
Stephen F. Fry Senior Vice President - Human Resources and Diversity
Age: 49
Bio & Compensation  - Reuters
Darren J. Carroll Senior Vice President - Corporate Business Development
Bio & Compensation  - Reuters
Enrique A. Conterno Senior Vice President and President - Lilly Diabetes
Age: 48
Bio & Compensation  - Reuters
Susan Mahony Ph.D. Senior Vice President and President - Lilly Oncology
Age: 50
Bio & Compensation  - Reuters